Seelos Therapeutics, Inc.
SEEL · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $1 | $9 | $19 | $9 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $9 | $19 | $9 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | $0 | $0 |
| % Margin | -1,267.1% | – | – | – |
| EBITDA | -$0 | -$0 | $0 | $0 |
| % Margin | -1,713.6% | – | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,719.6% | – | – | – |
| EPS Diluted | -7.73 | -21.48 | -22.29 | -12.88 |
| % Growth | 64% | 3.6% | -73.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |